Katrina Terwilliger
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,917 of the $3,392 with a category attached, or 86.0%. It is spread thinly across 39 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations.
Across 134 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$332
- Incyte Corporation$249
- Daiichi Sankyo Inc.$213
- Astellas Pharma US Inc$205
- Seagen Inc.$199
- AstraZeneca$189
- plus $2K from 33 others
What the payments were for
- Food & beverage$2,91786%
- Education$47514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $332 |
| Incyte Corporation | 8 | $249 |
| Daiichi Sankyo Inc. | 11 | $213 |
| Astellas Pharma US Inc | 4 | $205 |
| Seagen Inc. | 2 | $199 |
| AstraZeneca(2 entities) | 8 | $189 |
| Jazz Pharmaceuticals Inc. | 5 | $162 |
| Merck | 8 | $161 |
| Pharmaessentia USA Corporation | 3 | $156 |
| Regeneron Healthcare Solutions, Inc. | 4 | $121 |
| Springworks Therapeutics, Inc. | 1 | $112 |
| Johnson & Johnson | 4 | $93 |
| Gilead | 4 | $92 |
| Pfizer | 4 | $86 |
| Eisai Inc. | 4 | $74 |
| E.r. Squibb & Sons, L.L.C. | 3 | $72 |
| EMD Serono, Inc. | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $64 |
| Geron Corporation | 3 | $64 |
| GSK | 3 | $61 |
| Novocure Inc. | 3 | $61 |
| Genentech USA, Inc. | 3 | $59 |
| Legend Biotech USA Inc. | 3 | $47 |
| Iovance Biotherapeutics, Inc. | 2 | $47 |
| Lilly USA, LLC | 2 | $46 |
| Bristol Myers Squibb | 2 | $45 |
| Stemline Therapeutics Inc. | 2 | $39 |
| Syndax Pharmaceuticals, Inc. | 2 | $35 |
| Servier Pharmaceuticals LLC | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Immunocore Limited | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Bayer | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Amgen | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Array Biopharma Inc | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Fennec Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BESREMI$110
How this compares
$3,392 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Other family in Ocala
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.